Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

V Rodriguez-Freixinos; J Capdevila; M Pavel; A Thawer; E Baudin; D O'Toole; K Herrmann; S Welin; S Grozinsky-Glasberg; W.W. de Herder; JW Valle; J Herman; T Kolarova; C Bouvier; M Falconi; D Ferone; S Singh

doi:10.1016/j.ejca.2020.11.037

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

V Rodriguez-Freixinos, J Capdevila, M Pavel, A Thawer, E Baudin, D O'Toole, K Herrmann, S Welin, S Grozinsky-Glasberg, W.W. de Herder, JW Valle, J Herman, T Kolarova, C Bouvier, M Falconi, D Ferone, S Singh

Internal Medicine

Research output: Contribution to journal › Review article › Academic › peer-review

13 Citations (Scopus)

37 Downloads (Pure)

Abstract

Neuroendocrine neoplasms (NENs) are a heterogeneous family of uncommon tumours with challenging diagnosis, clinical management and unique needs that almost always requires a multidisciplinary approach. In the absence of guidance from the scientific literature, along with the rapidly changing data available on the effect of COVID-19, we report how 12 high-volume NEN centres of expertise in 10 countries at different stages of the evolving COVID-19 global pandemic along with members of international neuroendocrine cancer patient societies have suggested to preserve high standards of care for patients with NENs. We review the multidisciplinary management of neuroendocrine neoplasms during the COVID-19 pandemic, and we suggest potential strategies to reduce risk and aid multidisciplinary treatment decision-making. By sharing our joint experiences, we aim to generate recommendations for proceeding to other institutions facing the same challenges.

Original language	English
Pages (from-to)	200-214
Number of pages	15
Journal	European Journal of Cancer
Volume	144
DOIs	https://doi.org/10.1016/j.ejca.2020.11.037
Publication status	Published - Feb 2021

Bibliographical note

Funding Information:
Dr. Capdevila reports grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Ipsen, personal fees from Exelixis, grants and personal fees from Bayer, grants and personal fees from Eisai, grants and personal fees from Advanced Accelerator Applications, personal fees from Lilly, personal fees from Sanofi, personal fees from Merck Serono, grants from Astrazeneca, outside the submitted work.

Funding Information:
Ken Herrmann reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, other from ABX, personal fees and non-financial support from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees and non-financial support from Siemens Healthineers, non-financial support from GE Healthcare, personal fees from Astellas, and personal fees from yMabs, all outside the submitted work.

Funding Information:
Ms. Kolarova reports grants from Novartis Pharmaceuticals Corporation, grants from Advanced Accelerator Applications SA, grants from IPSEN PHARMA, grants from ITM Isotopen Technologien.

Funding Information:
Dr. de Herder reports grants from Ipsen, personal fees from Ipsen, personal fees from Novartis, personal fees from Pfizer,and personal fees from AAA, outside the submitted work.

Publisher Copyright:
© 2020 Elsevier Ltd

Research programs

EMC OR-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2020.11.037

Repub_133163.pdfFinal published version, 403 KB

Cite this

Rodriguez-Freixinos, V., Capdevila, J., Pavel, M., Thawer, A., Baudin, E., O'Toole, D., Herrmann, K., Welin, S., Grozinsky-Glasberg, S., de Herder, W. W., Valle, JW., Herman, J., Kolarova, T., Bouvier, C., Falconi, M., Ferone, D., & Singh, S. (2021). Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 144, 200-214. https://doi.org/10.1016/j.ejca.2020.11.037

@article{2ba9a8d3d6aa414bb11736b550610d51,

title = "Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era",

abstract = "Neuroendocrine neoplasms (NENs) are a heterogeneous family of uncommon tumours with challenging diagnosis, clinical management and unique needs that almost always requires a multidisciplinary approach. In the absence of guidance from the scientific literature, along with the rapidly changing data available on the effect of COVID-19, we report how 12 high-volume NEN centres of expertise in 10 countries at different stages of the evolving COVID-19 global pandemic along with members of international neuroendocrine cancer patient societies have suggested to preserve high standards of care for patients with NENs. We review the multidisciplinary management of neuroendocrine neoplasms during the COVID-19 pandemic, and we suggest potential strategies to reduce risk and aid multidisciplinary treatment decision-making. By sharing our joint experiences, we aim to generate recommendations for proceeding to other institutions facing the same challenges.",

author = "V Rodriguez-Freixinos and J Capdevila and M Pavel and A Thawer and E Baudin and D O'Toole and K Herrmann and S Welin and S Grozinsky-Glasberg and {de Herder}, W.W. and JW Valle and J Herman and T Kolarova and C Bouvier and M Falconi and D Ferone and S Singh",

note = "Funding Information: Dr. Capdevila reports grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Ipsen, personal fees from Exelixis, grants and personal fees from Bayer, grants and personal fees from Eisai, grants and personal fees from Advanced Accelerator Applications, personal fees from Lilly, personal fees from Sanofi, personal fees from Merck Serono, grants from Astrazeneca, outside the submitted work. Funding Information: Ken Herrmann reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, other from ABX, personal fees and non-financial support from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees and non-financial support from Siemens Healthineers, non-financial support from GE Healthcare, personal fees from Astellas, and personal fees from yMabs, all outside the submitted work. Funding Information: Ms. Kolarova reports grants from Novartis Pharmaceuticals Corporation, grants from Advanced Accelerator Applications SA, grants from IPSEN PHARMA, grants from ITM Isotopen Technologien. Funding Information: Dr. de Herder reports grants from Ipsen, personal fees from Ipsen, personal fees from Novartis, personal fees from Pfizer,and personal fees from AAA, outside the submitted work. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2021",

month = feb,

doi = "10.1016/j.ejca.2020.11.037",

language = "English",

volume = "144",

pages = "200--214",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Rodriguez-Freixinos, V, Capdevila, J, Pavel, M, Thawer, A, Baudin, E, O'Toole, D, Herrmann, K, Welin, S, Grozinsky-Glasberg, S, de Herder, WW, Valle, JW, Herman, J, Kolarova, T, Bouvier, C, Falconi, M, Ferone, D & Singh, S 2021, 'Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era', European Journal of Cancer, vol. 144, pp. 200-214. https://doi.org/10.1016/j.ejca.2020.11.037

TY - JOUR

T1 - Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

AU - Rodriguez-Freixinos, V

AU - Capdevila, J

AU - Pavel, M

AU - Thawer, A

AU - Baudin, E

AU - O'Toole, D

AU - Herrmann, K

AU - Welin, S

AU - Grozinsky-Glasberg, S

AU - de Herder, W.W.

AU - Valle, JW

AU - Herman, J

AU - Kolarova, T

AU - Bouvier, C

AU - Falconi, M

AU - Ferone, D

AU - Singh, S

N1 - Funding Information: Dr. Capdevila reports grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Ipsen, personal fees from Exelixis, grants and personal fees from Bayer, grants and personal fees from Eisai, grants and personal fees from Advanced Accelerator Applications, personal fees from Lilly, personal fees from Sanofi, personal fees from Merck Serono, grants from Astrazeneca, outside the submitted work. Funding Information: Ken Herrmann reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, other from ABX, personal fees and non-financial support from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees and non-financial support from Siemens Healthineers, non-financial support from GE Healthcare, personal fees from Astellas, and personal fees from yMabs, all outside the submitted work. Funding Information: Ms. Kolarova reports grants from Novartis Pharmaceuticals Corporation, grants from Advanced Accelerator Applications SA, grants from IPSEN PHARMA, grants from ITM Isotopen Technologien. Funding Information: Dr. de Herder reports grants from Ipsen, personal fees from Ipsen, personal fees from Novartis, personal fees from Pfizer,and personal fees from AAA, outside the submitted work. Publisher Copyright: © 2020 Elsevier Ltd

PY - 2021/2

Y1 - 2021/2

N2 - Neuroendocrine neoplasms (NENs) are a heterogeneous family of uncommon tumours with challenging diagnosis, clinical management and unique needs that almost always requires a multidisciplinary approach. In the absence of guidance from the scientific literature, along with the rapidly changing data available on the effect of COVID-19, we report how 12 high-volume NEN centres of expertise in 10 countries at different stages of the evolving COVID-19 global pandemic along with members of international neuroendocrine cancer patient societies have suggested to preserve high standards of care for patients with NENs. We review the multidisciplinary management of neuroendocrine neoplasms during the COVID-19 pandemic, and we suggest potential strategies to reduce risk and aid multidisciplinary treatment decision-making. By sharing our joint experiences, we aim to generate recommendations for proceeding to other institutions facing the same challenges.

AB - Neuroendocrine neoplasms (NENs) are a heterogeneous family of uncommon tumours with challenging diagnosis, clinical management and unique needs that almost always requires a multidisciplinary approach. In the absence of guidance from the scientific literature, along with the rapidly changing data available on the effect of COVID-19, we report how 12 high-volume NEN centres of expertise in 10 countries at different stages of the evolving COVID-19 global pandemic along with members of international neuroendocrine cancer patient societies have suggested to preserve high standards of care for patients with NENs. We review the multidisciplinary management of neuroendocrine neoplasms during the COVID-19 pandemic, and we suggest potential strategies to reduce risk and aid multidisciplinary treatment decision-making. By sharing our joint experiences, we aim to generate recommendations for proceeding to other institutions facing the same challenges.

UR - http://www.scopus.com/inward/record.url?scp=85098738559&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2020.11.037

DO - 10.1016/j.ejca.2020.11.037

M3 - Review article

C2 - 33370645

SN - 0959-8049

VL - 144

SP - 200

EP - 214

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

Abstract

Bibliographical note

Research programs

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this